Abstract | PURPOSE: DESIGN: Prospective, multicenter, double-masked, randomized, active-controlled trial. PARTICIPANTS: METHODS: MAIN OUTCOME MEASURES: Mean change in best-corrected visual acuity (BCVA) from baseline to month 12, and the proportion of patients with treatment-free interval ≥3 months at any timepoint after month 2. RESULTS: The mean change in BCVA at month 12 was +2.5 and +4.4 letters in the combination and monotherapy groups, respectively (P = 0.0048; difference: -1.9 letters [95% confidence interval, -5.76 to 1.86], for having achieved noninferiority with a margin of 7 letters). The proportion of patients with a treatment-free interval of ≥3 months at any timepoint after month 2 was high, but did not show a clinically relevant difference between the treatment groups. Secondary efficacy endpoints included the mean number of ranibizumab retreatments after month 2 (1.9 and 2.2 with combination and monotherapy, respectively [P = 0.1373]). The time to first ranibizumab retreatment after month 2 was delayed by 34 days (about 1 monthly visit) with combination (month 6) versus monotherapy (month 5). At month 12, mean ± standard error central retinal thickness decreased by 115.3±9.04 μm in the combination group and 107.7±11.02 μm in the monotherapy group. The mean number of verteporfin/ sham PDT treatments was comparable in the 2 groups (combination, 1.7; monotherapy, 1.9). The safety profiles of the 2 groups were comparable, with a low incidence of ocular serious adverse events. CONCLUSIONS:
|
Authors | Michael Larsen, Ursula Schmidt-Erfurth, Paolo Lanzetta, Sebastian Wolf, Christian Simader, Erika Tokaji, Stefan Pilz, Annemarie Weisberger, MONT BLANC Study Group |
Journal | Ophthalmology
(Ophthalmology)
Vol. 119
Issue 5
Pg. 992-1000
(May 2012)
ISSN: 1549-4713 [Electronic] United States |
PMID | 22424834
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Photosensitizing Agents
- Porphyrins
- Verteporfin
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Choroidal Neovascularization
(drug therapy, physiopathology)
- Combined Modality Therapy
- Double-Blind Method
- Female
- Humans
- Incidence
- Macular Degeneration
(drug therapy, physiopathology)
- Male
- Middle Aged
- Photochemotherapy
- Photosensitizing Agents
(adverse effects, therapeutic use)
- Porphyrins
(adverse effects, therapeutic use)
- Prospective Studies
- Ranibizumab
- Treatment Outcome
- Verteporfin
- Visual Acuity
(physiology)
|